US2022202713A1PendingUtilityA1
Curcumin Solubilisate
Est. expiryDec 19, 2032(~6.4 yrs left)· nominal 20-yr term from priority
Inventors:Dariush Behnam
A23L 2/56A61K 9/4808A61P 35/00A61P 25/28A61P 25/00A61K 9/1075A23L 33/10A23L 5/43A23L 27/10A61K 47/26A23D 7/0053A23V 2250/2112A23V 2002/00A61K 36/9066A61K 31/121A61K 31/12A61K 9/4858A61K 8/35A23L 2/52A23L 2/39A23P 10/30A23L 33/105
76
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A solubilize composed of curcumin in a quantity of less than or equal to 10% by weight, preferable less than or equal to 7.5% by weight, particularly preferable 6% by weight, and at least one emulsifier having an HLB value in the range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, wherein the average diameter of the micelles loaded with curcumin in between 5 nm and 40 nm, preferable between 6 nm and 20 nm, particularly preferable between 7 nm and 10 nm.
Claims
exact text as granted — not AI-modified1 . Solubilisate composed of
curcumin in a quantity of less than or equal to 10% by weight, preferably less than or equal to 7.5% by weight, particularly preferably 6% by weight, and at least one emulsifier having an HlB value in the range between 13 and 18, in particular polysorbate 80 or polysorbate 20 or a mixture of polysorbate 20 and polysorbate 80, wherein the average diameter of the micelles loaded with curcumin is between 5 nm and 40 nm, preferably between 6 nm and 20 nm, particularly preferably between 7 nm and 10 nm.
2 . Solubilisate according to claim 1 , characterized in that the width of the diameter distribution of the micelles ranges from approximately 4 nm to approximately 30 nm.
3 . Solubilisate according to one of the preceding claims,
characterized in that the total curcuminoid concentration in human blood plasma, measured one hour after oral administration of 500 mg curcumin in the form of the solubilisate according to one of the preceding claims, is approximately 500 ng curcuminoid per ml plasma ±100 ng curcuminoid per ml plasma.
4 . Solubilisate according to one of the preceding claims, characterized in that the total curcuminoid concentration in human blood plasma, measured over a period of 24 hours as the area under the total curcumin plasma concentration-time curve (area under the total curcumin plasma concentration-time curve AUC), is in the range of approximately 9,500 to approximately 10,000 nmol h/l.
5 . Solubilisate according to one of the preceding claims, characterized in that the turbidity of the solubilisate is less than 30 FNU, preferably less than 20 FNU, and particularly preferably is in the range between 0.5 FNU and 2 FNU, determined by scattered light measurement with infrared light according to the requirements of the ISO 7027 standard at a dilution of the solubilisate in water in a ratio of 1:1000.
6 . Solubilisate according to one of the preceding claims, characterized in that the turbidity of the solubilisate after 24 hours storage at 21° C. and pH 7 is less than 30 FNU, preferably less than 20 FNU, and particularly preferably is in the range between 0.5 FNU and 2 FNU, determined by scattered light measurement with infrared light according to the requirements of the ISO 7027 standard at a dilution of the solubilisate in water in a ratio of 1:1000.
7 . Solubilisate according to one of the preceding claims, characterized in that the turbidity of the solubilisate after 1 hour storage at 37° C. and pH 1.1 is less than 30 FNU, particularly preferably less than 20 FNU, and particularly preferably is in the range between 0.5 FNU and 2 FNU, determined by scattered light measurement with infrared light according to the requirements of the ISO 7027 standard at a dilution of the solubilisate in water in a ratio of 1:1000.
8 . Solubilisate according to one of the preceding claims, characterized in that the solubilisate contains up to 5% by weight water.
9 . Solubilisate according to one of the preceding claims, characterized in that the solubilisate contains between 12% by weight and 20% by weight glycerin.
10 . Capsule filled with a solubilisate according to one of the preceding claims, characterized in that the capsule is formed as a soft gelatin capsule or hard gelatin capsule, or as a soft gelatin-free capsule or as a hard gelatin-free capsule.
11 . Fluid containing a solubilisate according to one of claims 1 to 10 , characterized in that the fluid is selected from the group comprising foods, beverages, cosmetics, and pharmaceutical products.
12 . Fluid according to claim 11 , characterized in that the fluid comprises an aqueous dilution of the Solubilisate.Join the waitlist — get patent alerts
Track US2022202713A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.